{"ticker": {"uuid": "b16f8734-4091-49ae-8e78-1ffb3a8b97d8", "symbol": "KNSA", "name": "Kiniksa Pharmaceuticals Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbDRaRW43YnZiU2s5WnppTmNhR1ZkMzdaOXlES19oak15eHJIaUNLT2E5dThtOHFtMklWVG8wVzBKNFRXa2hHZVBnYU4zWEF4UlhsWmQteUdYMDQxYVV0WkIycW9Rbk5vZExOM3dYVVhQaUlUYk5UNDk5OXB3azRuMTRUYWZ4RnVtcXdNV24tbklqWHFBWEFGQmw4V0l1NEQtX25iY1FMVVVpaHIzcjdrazhIdjJZZXRUSnpSRFZxd000R2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T15:08:30+00:00", "published_display": "15 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPZ1FFQWhiRzhoUTgydVp2VTFOYmVrTGNWRnJmYnZDZ21zNHhnTDgyVWJIejhYRjVDWE5oeklXS0Z5VG5FUTNuS203RjdWVV9pNFpFT0twV1Ywa056YVk0a09zWWRubXpHV3lYQnlqVFJSV25kd2QyRW1vQUU1M0tFcjNCeDlQN1NJRTQxU01aeXM1bEstckhiblZteUxEOGRRWm1wY1dVWEVEcEVnelZ3ZUdtUWI3d2Y5LTU3eDNqME1wcTE3djZqb0VsY1JvdU8ycVkxbEtnalVSZTNJeHRFM24xd3ZVdU52d242Q283SzNmMDNOOU9R?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T12:45:41+00:00", "published_display": "13 Jul 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQblVfdlRvdENtMFRqNmJOYTY3MWFXcVF5SzRYWGtTUE5iLVAtOTdrejA3MXhybnNXN1YxSWo5THI5R3VpUTE5SkpPYndUb3BRYTdRdGxsTmlCZmQwaE16MkdoWFhIX0w2UzNIMnktZWR0RENKQno4WllNUnBnRDBBTEx3bm94OEVCbVg4dVFzS1lCX0x6Tm9XVDNGeDJ5bDhCNi1ZeHN2T01EUEFJRlpGUnNuQV94cF9nYmJ2eGYwMmlXNDNKeDBLWG1KUmdqS3gyeThVTXVNYjBmS0U?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T18:18:05+00:00", "published_display": "12 Jul 2026 18:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of \"Buy\" from Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNY3dIYjMxR1JHbkV1aWZGQTRSazRDZi1oakdJLXdILXdTbGxsbEtfLTd0MVlhOHR3N2J6Ujd1UUFPUlRNQkFCWDZmV1VyTm5kQUFTRzU5WGFpcERTZGcwSVB5eDBFYVczeXRGa1JvcS11YTJZamZmU0dVbExRZEtIWnNBN0dYRWw2bDUzZlR3MWNzeWdUQ1MtZUNfQlRPMnpZQUZ2MU9Cd2Z1YkV1QWNzWWM4TUxFZWZtZXVnU0dtaGI1TGJRYlhIdXlOa2pDcHpudVF1Zl9ZQmpMQ1Q3R2FkbTgyWUdPSXpW?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T18:17:58+00:00", "published_display": "12 Jul 2026 18:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kiniksa-pharmaceuticals-international-knsa-joins-061141971.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T06:11:41+00:00", "published_display": "09 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Stock Fully Valued?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T01:03:05+00:00", "published_display": "09 Jul 2026 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 7.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQYjU3bE5Wb2VlZUpSM000UEc3NE5VS0NEc1I2ekdXaGxSemlYT2kyaWJwc3NZX3JGZVl1ZmhvTUhIQ1ZSekkzb1JOOTllRjM4b2FlY1JEbng5eUFPR2gwczlTMlhpQWVubkZkRTNhT0d5UmdSMUo3bEdpRFROMzh0eTVidEo0Q2pGWG1mbnJiQWRDOUltRENKQVEtcmZrNVh5RUstTDRIM3U2N0FpaFFvdVhsb19qTlNobnRnaGpwQTZiNzZMNVgzZ0VKYTNRdFpYQm1v?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-08T00:32:52+00:00", "published_display": "08 Jul 2026 00:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Performance share awards at Kiniksa (NASDAQ: KNSA) tied to KPL-387 FDA goals", "summary": "Kiniksa Pharmaceuticals International's Chief Strategy Officer, Dhiraj H. Malkani, received various equity awards on July 1, 2026, including performance share units, performance share options, and restricted share units. The vesting of these performance-linked awards is contingen", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-fcb3ec8a7d9b.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:10:17", "published_display": "07 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Broad Russell Index Inclusion Reshape Kiniksa Pharmaceuticals' (KNSA) ARCALYST-Centered Growth Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQZjVUOEh6RWZFUHV6UHRWSUZKRGZWQXdzZ2lkYUl4UTBDNFFEci1ibEw1TXJvVHkzdE1nLUJ0dkIzaHhESDZHRHc0eHhNQUo4NlltdS1Iekk2ZHdNNTFscldZN285dGFCMnc5THFiTWdrLUNVSEs4ZHN6SjQtVFNGbFc1MUlaUEpWa3ZBdkkybmdrV2Ewc2hVXzBBc0o2ak93RDZBOHMxZkZVbjNadzZMT2dudGRNUzNmRTBPLTkySUExd3BGUV9kaENJWUlkQlpKYmVMQ1QyRDVaN0pxRFBYX3ZHb1dyb09tMVREM0EzbGNEQVBLVS1paVZlZHE1YXVj0gGGAkFVX3lxTFBObkJOU25VLUVzR1ZTRElqWnRleTllZUZDajZmN2N3SFFUcEwyM2dIRi1CSFZYRDJLQ0VIY002ZFVpNk9ONlNtMTF4NFM1ZmZURUkybVdjY1RDUHIwWmlEQVhrRUxsMzBwYnlCWGVBZ0ZrUlJqWjhzeE5ELVVfMlIyUmZCWXZmbE1RWVlmZ2dPUnA5X09leEJTNXJRanpIbDVqSndIWm0xYnF1RmpzTXpKbDB2VU5sakNrVDl3SDgxYUJDNjZVM1pqOHBWeFFHNmdJbUtvVF9RZERqZUU1TlZmUUEtQ3A0YVFYeTJOMjFuQkZ3ZkdzeW5aTE94R1lWZGtkZzluY1E?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T13:44:02+00:00", "published_display": "07 Jul 2026 13:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals updates investors on rare disease portfolio and Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOWS1KdUtzVGZadVlBa3ZneXhwT0g0d1VQVERWZ2JrWk5qMU1qY0hYNW9FRWlCZl84VTJ1c0RUQjRPaFhqS3VhNjNRNFAzVnFXM0JZeDJyWmxTN0ROX2dVRGtHWDV3RGtSWUpYVDVFaXFrX0ZNeU1nMEszdEROT2x3aElIelZJWnFLVzNhbFEzM3ZnQjNXX29HcjM2ckxtSXRKZWJ2UnJ5V05jM0U2R1lOdlRFREtTc1JyWEJsRHEyUmZjZkFxUXBCR01n?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T13:36:45+00:00", "published_display": "07 Jul 2026 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQcWl6V3FGVGl0b1hmdkxhdVFCNmhlcmNUN2RSamdjMXZXelhRdXRyOUE5RVIxTHZET3J2VnRoYmlTTEhaOW0zMlhYVi1IaXYwSmhOcXpJRzMyZUtsTXlRUHpHanMwNnNMTjJhVGEtNG9XZmYtOVJ4UE56VGJXaGRodmw4WDViZnVLd2pSOXVqN1RQWWU3M2ZYRTJQcHZmRGNTZGZxSUVTaFl4bGFXVXZ4Xw?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) Chief Strategy Officer named as insider in Form 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQZ0FWWU5oUkl4MjBLdWhJQWNLa3JRZ1ZxQlVhOFNobXptSnprdVZLMDJuREdGdlcxR2c2dUpmVVByZ3I5Z0VmMFZwclp3cnJ2SXE4X0ZsanVGa1VaTURsQlYxbTRRMm9SMlRSQ0xyNmFyQkRDQUxkZ0FlcE1ya3RHSnFwRjBwWnA0cElBT2VIYnRCbUtNTzF1UUtGOEtlaXotdWlLcTcwcVN4NkJKQy1DSlpTTG5XLTAtU0dhU3Y4ZFVxYkpjLUFJMEFEcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals updates investors on business progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNb0VhR0pEbWlTeEp5bVhTWDZJU0k5UXkzbTlNWXFtdm5yamRJZFVCYTRCV25QTkFRLTlZNmUxNjFHUERhWm5zaUE3cW40UmpPVmp4T2pqRTRZdFNTTkRidWlMWDV3bXFSTFFsOUNBV3dYRHIwaVRBV1V1c3dyRVZjdFhUZjhBZk5aeUdnaVkzaHJPLU4zRVpucUxnVmpmV0NZcktib0xuU2EyRkQ0NHlfNXRmaFVfRjdfM1haNmRR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T16:16:43+00:00", "published_display": "03 Jul 2026 16:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOdU5uYXVxQUY5TVdoZExKRFJGd0hpTkVDcnlFQTFlNXcwNEZxTHZQVEptanBoTmNoMjNWaEliem5LYXBQUnRneE5CaWpkUW9TeWQ0NldidV9NckxBR1JMQ1JTTHRNWEhheG9nNDREb3dEeFgwaUN5eW1EV0ZydVh0UGtGV3UzaTFJNDF6ZmRwSmVsX2lydlhVUDlqNXh2Z0d0Y1VySXBGRnNjR09tdFlqbDZ3?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNd0JfRVdaVHRhOTktQk42bW1lUGltMWVzSXo1djNJeDNZay1JaGdtQldFMmw0d255c2hPOEF2MkZjdFl4Y0M2NEplQ0Y5b0JBc1hISlBiam9CUHRyVjZkWm83MTNoeDZzdnVaZHZKTHdlRmlvNW5saUwtME9Tc0pFdDQtRHRGNnA4S3JwWURjQ05sVGtRZ3FwZEh2RnBTVWY1UVZ3OWYwVWJhZUowM2toWg?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 5.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQa0RZV1FERVJRaHg5OWw4SUxCYTl1VjlwTXZrRXNKeDBzejhacEE3RkFKY0oyd0UwcHllcFNWMHk1N0RRYjZfcHMzWFdnQUNYNVh1b3JHWGJvWlVhNEpTXzFlV3ROXzlpNTNfMnN6Nm1WcTM2NmVTYS1YUHRKbXVBaUhZR0xIaEVPYWZLNkRJNlo0RzBvVDlTMDNfeWFYaVR2S3hhU2FHQW5pZUxkRHhDQkdhalhIYzRYb2VlaHZZMVBGUWJoNUtWbTU5VXJLQ3VpZzE0?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-30T00:01:06+00:00", "published_display": "30 Jun 2026 00:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Kiniksa Pharmaceuticals International to $72 From $59, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-kiniksa-110951947.html", "source_name": "MT Newswires", "published_at": "2026-06-29T11:09:51+00:00", "published_display": "29 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (BOATS:KNSA)", "summary": "This article provides an overview of Kiniksa Pharmaceuticals International, plc (KNSA) stock, including its financial actuals and estimates. It details analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net income, and EBI", "url": "https://www.tradingview.com/symbols/BOATS-KNSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:07", "published_display": "26 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International PLC (KNSA) Stock Down 3.8% but Still Overvalued -- GF Score: 56/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxON1ZzdVVnSHBtdkhzNlByUmU1ajZwLWlpbnlEVkpXa3B3aVYtOFNSbjdLZ2Zya0hRTXAxRXc4RDJXWGszZnU4ZmJxZFhTRmN0V1hURkhQMEJSQXZMWW9MN2lkZXRoMDBRSF80TDlNdjREdWRiVWVJREU3R0doUTJHd0djc1pJbkxrdkgtMlJaaFZMQy1HQWNHM2lWWm5qYjVLRVNkZTdWN2h5cm1oMmxzTmM3bjhmVzE4NlpYMEZUWW9mbGV6NTNucEpGMUNaSFpj?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-26T00:21:25+00:00", "published_display": "26 Jun 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KNSA/N Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Kiniksa Pharmaceuticals International, plc Class A (KNSA/N) stock, including analyst price targets and future predictions. It details financial metrics such as EPS, revenue, market capitalization, and upcoming earnings dates, along with histor", "url": "https://www.tradingview.com/symbols/BMV-KNSA/N/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:07", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQci1mNXA5eDAwUG9ic1NOMmxzbWlKVUg3bTYtWDB6U2p5SGVkYTlLMEJUWW5BalV4OXRSd1JlWVgyNS12Q19sdUYybjEwRnFfTXJQLXR3Tl91aTZiMnJkbW82eTE2VnJzZmd0UTBvaHYzNl8tQkpBR0lyVlg2cnVwLU5sRk1EOXoyWHFfZXAyZDEyQUtJSTlwcmlZaW9OV0g2WjgxS0ZzaENyQzY1aUNkNWN3?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals stock hits all-time high of 59.89 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNa0lfSm9kRm84ZW9sQ3hSaDVaajBicXVPVkxMd29saVFIck1uUFNPMkowR2pFUnlJTlFtLXNqNzJaZFJMc0NyNzFVNkZWTzE4Ny16M0IzU2gxY1k5dlpsQkluZFBmY1JNQk1WdnpCR1VSVVg3NHdyUS15UGQ0T3dUaF9tODFKdFUza1pueEhtMnp6ZjU1WGI5T2ZwbDNOYi14UG5zT2o1STRZUDFEUFVnQ29KdzYtVUk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNbnY1ZmFRUm11TVFqNWZIUUlrRkZUUGRuR1VmM1RXZ0F0MklRdjBqZHZfSEJWRDREMkN6R3dDaFIyalpGRkJZSXJQbDgyY0drTE5SenV1SWpBOWJORGFFN2xwbkpoQ0hRREZHQzFacDR3dHlVSzVFZk8ySE4zRjJMRWRRb1FRMHViUzZHdEdPOHJpUHU5dFRHWjBSWWJkMTZJalFlcmZQQ1BwWU0?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPa0NEazl3TldfSVNlUFRZZGlsemRqWDhtdGlBdTZITUZnRWRhVDhsVThmWUN0TkFjVjhEZXBOS3djVUxucEJMQjJYSS04ZUJkMGJfZU9pRW1QbGFQU0RndEdHa2E2RmJRR19McVQzSk5USmhMYkpFaHFCOXRZT245MlhyREE4SGdPTmppdWpKbEVMTVlfbmY0eGhCaTVUd0xRQlB6S1FwcEhvOUhvbzJuTA?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director receives RSUs and options in equity grants", "summary": "Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported exercising 2,799 vested Restricted Share Units (RSUs) and receiving new equity grants on May 29, 2026. These new grants include 2,026 RSUs and options for 12,158 Class A Ordinary Shares with an exercise p", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-6525fa05d906.html", "source_name": "Stock Titan", "published_at": "2026-06-03T14:39:39", "published_display": "03 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) awards RSUs and options to Baker-affiliated board representatives", "summary": "Kiniksa Pharmaceuticals International, plc (KNSA) granted restricted share units (RSUs) and non-qualified share options to three Baker-affiliated directors, including Felix J. Baker. Each director received 2,026 RSUs and 12,158 share options with a strike price of $48.38, as comp", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-29aaf6ed096a.html", "source_name": "Stock Titan", "published_at": "2026-06-03T07:39:39", "published_display": "03 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director Malley exercises RSUs and receives new option grant", "summary": "Kiniksa Pharmaceuticals director Thomas Malley recently exercised 2,799 Restricted Share Units and received new grants, including 2,026 RSUs and a share option for 12,158 Class A Ordinary Shares, with an exercise price of $48.38 per share. These transactions, which occurred on Ma", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-35d47ea1fd3a.html", "source_name": "Stock Titan", "published_at": "2026-06-03T02:40:25", "published_display": "03 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares", "summary": "Kiniksa Pharmaceuticals director Tracey L. McCain exercised 2,799 Restricted Share Units (RSUs) converting them into Class A Ordinary Shares, increasing her direct holdings to 15,345 shares. She also received new grants of 2,026 RSUs and share options for 12,158 Class A Ordinary ", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-25529e22b160.html", "source_name": "Stock Titan", "published_at": "2026-06-03T00:39:39", "published_display": "03 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards", "summary": "Kiniksa Pharmaceuticals director Cole G. Bradley reported exercising 2,799 Restricted Share Units (RSUs) into Class A Ordinary Shares, increasing his direct holdings to 15,345 shares. He also received new equity awards, including 2,026 RSUs and options on 12,158 Class A Ordinary ", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-315cd0af69a8.html", "source_name": "Stock Titan", "published_at": "2026-06-03T00:39:39", "published_display": "03 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director exercises RSUs and receives new option grant", "summary": "Kiniksa Pharmaceuticals International, plc director Richard S. Levy recently exercised 2,799 Restricted Share Units (RSUs), converting them into Class A Ordinary Shares, bringing his direct holdings to 21,956 shares. Concurrently, he received new grants including 2,026 RSUs and a", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-4799ca5b4afc.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:39:39", "published_display": "02 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director Popovits exercises 2,799 RSUs and receives 12,158-share option grant", "summary": "Kiniksa Pharmaceuticals International, plc director Kimberly J. Popovits reported routine equity compensation transactions. On May 29, 2026, she exercised 2,799 Restricted Share Units (RSUs) and received new grants of 2,026 RSUs and a share option for 12,158 Class A Ordinary Shar", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-0e7bd5ac068b.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:39:39", "published_display": "02 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO-linked trust converts 900,000 Kiniksa (NASDAQ: KNSA) Class B shares", "summary": "A trust associated with Kiniksa Pharmaceuticals' CEO, Sanj K. Patel, converted 900,000 Class B Ordinary Shares into Class A Ordinary Shares. This transaction, a non-cash derivative conversion at $0.00 per share, resulted in the trust holding 951,794 Class A and 626,160 Class B sh", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-a309cc6b8b2f.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:39:39", "published_display": "02 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc Files Form 8-K Detailing Annual Meeting Results and Company Information", "summary": "Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) announced the results of its 2026 Annual Shareholder Meeting held on May 29, 2026. All proposals, including the re-election of directors, appointment of auditors, and approval of executive compensation, were passed by shar", "url": "https://www.minichart.com.sg/2026/05/31/kiniksa-pharmaceuticals-international-plc-files-form-8-k-detailing-annual-meeting-results-and-company-information/", "source_name": "Minichart", "published_at": "2026-05-31T10:39:58", "published_display": "31 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals Files 8-K Disclosing Waiver of Share Conversion Rights with Baker Brothers Life Sciences 9", "summary": "Kiniksa Pharmaceuticals International, plc has entered into a Deed of Waiver with its major shareholder, Baker Bros. Advisors LP, restricting Baker Bros.'s ability to convert shares if it would result in beneficial ownership of more than 49.9% of Kiniksa's voting rights. This agr", "url": "https://www.minichart.com.sg/2026/05/27/kiniksa-pharmaceuticals-files-8-k-disclosing-waiver-of-share-conversion-rights-with-baker-brothers-life-sciences-9/", "source_name": "Minichart", "published_at": "2026-05-31T10:09:21", "published_display": "31 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Shareholders Reelect Directors and Approve Auditor Mandates", "summary": "Kiniksa Pharmaceuticals shareholders reelected Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart as Class II directors to serve until the 2029 Annual Meeting. They also approved PricewaterhouseCoopers LLP as the U.K. statutory auditor and U.S. independent registered public a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/KNSA/pressreleases/2219537/kiniksa-shareholders-reelect-directors-and-approve-auditor-mandates/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T02:40:25", "published_display": "31 May 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) investors approve board, PwC auditor roles and pay", "summary": "Kiniksa Pharmaceuticals International, plc shareholders approved all proposals at their Annual Meeting on May 29, 2026. This included the re-election of three Class II directors (Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart), and the appointment and remuneration of Pric", "url": "https://www.stocktitan.net/sec-filings/KNSA/8-k-kiniksa-pharmaceuticals-international-plc-reports-material-event-3e96291ecc7c.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:10:06", "published_display": "29 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) sets 49.9% voting cap for Baker Bros. conversions", "summary": "Kiniksa Pharmaceuticals International, plc has entered into a deed of waiver with Baker Bros. Advisors LP and affiliated funds, capping their ability to convert shares if it results in them beneficially owning more than 49.9% of Kiniksa's outstanding voting rights. This agreement", "url": "https://www.stocktitan.net/sec-filings/KNSA/8-k-kiniksa-pharmaceuticals-international-plc-reports-material-event-8c00e74a18e5.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:40:38", "published_display": "26 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baker Bros sets 49.9% voting cap in Kiniksa (NASDAQ: KNSA)", "summary": "Baker Bros. Advisors has filed an amendment to its Schedule 13D for Kiniksa Pharmaceuticals International, plc, disclosing a Deed of Waiver that limits their voting rights in Kiniksa to 49.9%. This agreement prevents the conversion of certain share classes if it would cause their", "url": "https://www.stocktitan.net/sec-filings/KNSA/schedule-13d-a-kiniksa-pharmaceuticals-international-plc-amended-majo-a221559176c3.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:40:38", "published_display": "26 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdlNHN3N2dG5VeTM4b0RYdWN2c1lRdkhHQWFvT3hKeHV3RjJibkJKdHF1UG9kVVdEbkswYnU0dUE2OE1DQXpUZTlLN0wxX25VUmNJMnY0QTJ5V05iLXIxT0hLNHp2OWF2MGJmMERXVDI1aW9SNnpMMmhncnV1OW1zbXVleWozLVdwLTNOb1FzXzlUVU5UNk03OGptd05lVVpsSXE5LW83dDhlSlk?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZExEV0FialpsWWQ4aVpJY1J5OEZaeEhvYnJ5c0NDdEMwMVVGMkVGQkpQRWppNlBqN1hiYk54dTJXWTJUNmR3Yno2V0JZTUQ3YTlkLXlrUGpiNXBTTU1hQXlhRHBlRURobjE1aTBHOW04OGE0V216UUl2RUdLRWhMV2tXdkp6S29ua2o5YUxRVjFNOThjdURWZEZ4dXlWSGZhRlIwWDlmTVB3am5Ra2lEc2pLbmx4UUk?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC amends filing showing 6,787,700.23 Kiniksa holdings (KNSA)", "summary": "FMR LLC has filed an amendment to its Schedule 13G, reporting beneficial ownership of 6,787,700.23 shares of Kiniksa Pharmaceuticals International (KNSA) Class A common stock. This updated filing indicates that FMR LLC holds 14.8% of the class. The disclosure specifies that FMR L", "url": "https://www.stocktitan.net/sec-filings/KNSA/schedule-13g-a-kiniksa-pharmaceuticals-international-plc-amended-pass-bdd4f0e1c3f4.html", "source_name": "Stock Titan", "published_at": "2026-05-06T15:39:57", "published_display": "06 May 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options", "summary": "Kiniksa Pharmaceuticals International, plc's Chief Medical Officer, John F. Paolini, executed an exercise-and-sell transaction on May 1, 2026. He exercised options to acquire 58,424 Class A Ordinary Shares at $10.36 per share and simultaneously sold the same number of shares in t", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-704661f9631f.html", "source_name": "Stock Titan", "published_at": "2026-05-05T20:38:43", "published_display": "05 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026)", "summary": "Kiniksa Pharmaceuticals International plc announced the resignation of its Chief Strategy Officer, Eben Tessari, effective May 15, 2026. Mr. Tessari will transition to a consulting and advisory role for the company's Science and Research Committee, assuaging concerns about abrupt", "url": "https://www.minichart.com.sg/2026/05/02/kiniksa-pharmaceuticals-international-plc-files-8-k-announces-consulting-agreement-details-and-company-information-april-30-2026/", "source_name": "Minichart", "published_at": "2026-05-03T01:09:33", "published_display": "03 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan", "summary": "Kiniksa Pharmaceuticals International, plc CEO Sanj K. Patel exercised options to acquire 48,565 Class A Ordinary Shares at $30.93 per share and subsequently sold all of them in an open-market transaction at a weighted-average price of $54.02 per share. This transaction was execu", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-40bdb8feb6ff.html", "source_name": "Stock Titan", "published_at": "2026-05-01T20:39:39", "published_display": "01 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcHU0VGt5U1duaFU5WlZNekdKbllleVJvWFBpWDYySU8zSDI5RGg4cHljQlE2SFhTNjM1MVpEaWlpYmliRFFrRDNVQ2RKeGhyRDdtT0M2TjFzaFZRTXZrRGh6bGlnN2wtOE9wZ3lGcXF2V0M5Z3hGcGtRbGlBMXFVaE5TOE95cndCR19xaFA3clJyenQ4Vmh4TmNlU2hybDB1VmFEd0RfbzhOa3JrYm45XzVGY1A?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) CEO\u2019s plan-based option exercises and 508K share sales detailed", "summary": "Kiniksa Pharmaceuticals International, plc CEO Sanj K. Patel exercised options for 508,339 Class A Ordinary Shares and subsequently sold an equal number of shares between April 28-30, 2026, at prices ranging from approximately $50.00 to $54.23 per share. These transactions were e", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-a8fe8e7a9761.html", "source_name": "Stock Titan", "published_at": "2026-04-30T22:10:13", "published_display": "30 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms", "summary": "This article provides a comprehensive overview of Kiniksa Pharmaceuticals International, plc's (KNSA) SEC filings available on Stock Titan. It details the types of filings, such as 10-K, 10-Q, and 8-K, and explains their importance for investors tracking financial results, clinic", "url": "https://www.stocktitan.net/sec-filings/KNSA/page-10.html", "source_name": "Stock Titan", "published_at": "2026-04-29T23:09:14", "published_display": "29 Apr 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan", "summary": "Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised options to acquire 13,099 Class A Ordinary Shares at $14.33 per share and subsequently sold them at a weighted average price of $50.10. This transaction was conducted under a pre-arranged Rule 10b5-1 pla", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-fa45bcf31958.html", "source_name": "Stock Titan", "published_at": "2026-04-29T21:08:39", "published_display": "29 Apr 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) insider sale and cashless exercise flagged in Form 144", "summary": "Kiniksa Pharmaceuticals International, plc filed a Form 144 detailing proposed and recent insider sales of Class A Ordinary Shares. The filing indicates a cashless exercise broker payment scheduled for April 28, 2026, and a prior sale on April 6, 2026, of 7,278 shares by Sanj K P", "url": "https://www.stocktitan.net/sec-filings/KNSA/144-kiniksa-pharmaceuticals-international-plc-sec-filing-5d9f9ad7448c.html", "source_name": "Stock Titan", "published_at": "2026-04-28T20:38:51", "published_display": "28 Apr 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) CAO sells 6,625 shares in Rule 10b5-1 trade", "summary": "Kiniksa Pharmaceuticals International, plc's Chief Accounting Officer, Michael R. Megna, reported the sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and after the sale, Megna", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-2779e2d1f8d2.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:38:47", "published_display": "13 Apr 2026 20:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan", "summary": "Kiniksa Pharmaceuticals International, plc's Chief Operating Officer, Moat Ross, sold 1,703 Class A Ordinary Shares at $46.69 per share on April 9, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on November 13, 2024. Following the s", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-f0b1688f50bc.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:38:47", "published_display": "13 Apr 2026 20:38", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) Form 144: 6,625 Class A shares tied to restricted stock lapses", "summary": "Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 indicating proposed dispositions of 6,625 Class A ordinary shares. These shares are linked to restricted stock lapses that occurred on April 1, 2026 (4,359 shares) and April 7, 2026 (2,266 shares). This admini", "url": "https://www.stocktitan.net/sec-filings/KNSA/144-kiniksa-pharmaceuticals-international-plc-sec-filing-67ea559f7c7a.html", "source_name": "Stock Titan", "published_at": "2026-04-09T19:39:41", "published_display": "09 Apr 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa\u2019s Heart\u2019s Home Campaign Targets ARCALYST Growth In Pericarditis Market", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Profitability Shift Tests Bullish High Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbDRaRW43YnZiU2s5WnppTmNhR1ZkMzdaOXlES19oak15eHJIaUNLT2E5dThtOHFtMklWVG8wVzBKNFRXa2hHZVBnYU4zWEF4UlhsWmQteUdYMDQxYVV0WkIycW9Rbk5vZExOM3dYVVhQaUlUYk5UNDk5OXB3azRuMTRUYWZ4RnVtcXdNV24tbklqWHFBWEFGQmw4V0l1NEQtX25iY1FMVVVpaHIzcjdrazhIdjJZZXRUSnpSRFZxd000R2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T15:08:30+00:00", "published_display": "15 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPZ1FFQWhiRzhoUTgydVp2VTFOYmVrTGNWRnJmYnZDZ21zNHhnTDgyVWJIejhYRjVDWE5oeklXS0Z5VG5FUTNuS203RjdWVV9pNFpFT0twV1Ywa056YVk0a09zWWRubXpHV3lYQnlqVFJSV25kd2QyRW1vQUU1M0tFcjNCeDlQN1NJRTQxU01aeXM1bEstckhiblZteUxEOGRRWm1wY1dVWEVEcEVnelZ3ZUdtUWI3d2Y5LTU3eDNqME1wcTE3djZqb0VsY1JvdU8ycVkxbEtnalVSZTNJeHRFM24xd3ZVdU52d242Q283SzNmMDNOOU9R?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T12:45:41+00:00", "published_display": "13 Jul 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQblVfdlRvdENtMFRqNmJOYTY3MWFXcVF5SzRYWGtTUE5iLVAtOTdrejA3MXhybnNXN1YxSWo5THI5R3VpUTE5SkpPYndUb3BRYTdRdGxsTmlCZmQwaE16MkdoWFhIX0w2UzNIMnktZWR0RENKQno4WllNUnBnRDBBTEx3bm94OEVCbVg4dVFzS1lCX0x6Tm9XVDNGeDJ5bDhCNi1ZeHN2T01EUEFJRlpGUnNuQV94cF9nYmJ2eGYwMmlXNDNKeDBLWG1KUmdqS3gyeThVTXVNYjBmS0U?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T18:18:05+00:00", "published_display": "12 Jul 2026 18:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of \"Buy\" from Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNY3dIYjMxR1JHbkV1aWZGQTRSazRDZi1oakdJLXdILXdTbGxsbEtfLTd0MVlhOHR3N2J6Ujd1UUFPUlRNQkFCWDZmV1VyTm5kQUFTRzU5WGFpcERTZGcwSVB5eDBFYVczeXRGa1JvcS11YTJZamZmU0dVbExRZEtIWnNBN0dYRWw2bDUzZlR3MWNzeWdUQ1MtZUNfQlRPMnpZQUZ2MU9Cd2Z1YkV1QWNzWWM4TUxFZWZtZXVnU0dtaGI1TGJRYlhIdXlOa2pDcHpudVF1Zl9ZQmpMQ1Q3R2FkbTgyWUdPSXpW?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T18:17:58+00:00", "published_display": "12 Jul 2026 18:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Upside Already Priced In?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kiniksa-pharmaceuticals-international-knsa-joins-061141971.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T06:11:41+00:00", "published_display": "09 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Joins Russell Indexes, Is The Stock Fully Valued?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQUUJldDZLRURsMmRkVjFjMzFhSjdkLXpUYXRDLTJaMWczQzg4VHlhWkRzT2pRa1JiVTdXNlgzTlh3cnI0cnozSXI1N2Nwc0NCQUt3c05tMEg3M0IxTmFZLW5mV0Y1RklXRk1waDhMVnZlTkQyeEdsZXVmaEZDYnhEZFRoN1BqcF9UdDJtNTBtSW5hdDJ2S2xMZmlSdUNlSllYZC1qOW9OWWM3U2NreUk1cTMyRm5BaGpLa0ZWQVkyUkNsZTl4VmxKUHlUTVVYVkE2ZUlzdWE1VkFZdU5JWER4em9CaHctYkhyMWxVS1F0aXFtTzV1V3RBazRlV3ZRNi1y0gGGAkFVX3lxTE5DYXFvM1lieXdPVHcxS1hOanVHX3FBR082YldlYjRWcHV2cnVSQW43OGdJeU13eFN4TV82VFQ4R1pDLVZQQy1iZF9kTk9lLWJ0R1ZoRkc2UXNKT053YlR4dnZQUWZSX3lCN2lacDk2TWVGSXpLTi1ZVVVQVlZZeC0xY21zdms0ZFBja2Y2S0JWdGpVbEJpeVg2SkNXSlJmQkJ3N1ZRd0hJRmxvbzNwTDQ3X2dLeEczZ3h3SHRnbk5qamVmeHBTYXpVMWVPN0R1YzJoeFdiLXBTaGVsWmxyLUZyakQyamhYdExicHQxOF8xanJfNGxkdnNMNUNCMF9LZFpyVnI0LWc?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T01:03:05+00:00", "published_display": "09 Jul 2026 01:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 7.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQYjU3bE5Wb2VlZUpSM000UEc3NE5VS0NEc1I2ekdXaGxSemlYT2kyaWJwc3NZX3JGZVl1ZmhvTUhIQ1ZSekkzb1JOOTllRjM4b2FlY1JEbng5eUFPR2gwczlTMlhpQWVubkZkRTNhT0d5UmdSMUo3bEdpRFROMzh0eTVidEo0Q2pGWG1mbnJiQWRDOUltRENKQVEtcmZrNVh5RUstTDRIM3U2N0FpaFFvdVhsb19qTlNobnRnaGpwQTZiNzZMNVgzZ0VKYTNRdFpYQm1v?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-08T00:32:52+00:00", "published_display": "08 Jul 2026 00:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Performance share awards at Kiniksa (NASDAQ: KNSA) tied to KPL-387 FDA goals", "summary": "Kiniksa Pharmaceuticals International's Chief Strategy Officer, Dhiraj H. Malkani, received various equity awards on July 1, 2026, including performance share units, performance share options, and restricted share units. The vesting of these performance-linked awards is contingen", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-fcb3ec8a7d9b.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:10:17", "published_display": "07 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Broad Russell Index Inclusion Reshape Kiniksa Pharmaceuticals' (KNSA) ARCALYST-Centered Growth Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQZjVUOEh6RWZFUHV6UHRWSUZKRGZWQXdzZ2lkYUl4UTBDNFFEci1ibEw1TXJvVHkzdE1nLUJ0dkIzaHhESDZHRHc0eHhNQUo4NlltdS1Iekk2ZHdNNTFscldZN285dGFCMnc5THFiTWdrLUNVSEs4ZHN6SjQtVFNGbFc1MUlaUEpWa3ZBdkkybmdrV2Ewc2hVXzBBc0o2ak93RDZBOHMxZkZVbjNadzZMT2dudGRNUzNmRTBPLTkySUExd3BGUV9kaENJWUlkQlpKYmVMQ1QyRDVaN0pxRFBYX3ZHb1dyb09tMVREM0EzbGNEQVBLVS1paVZlZHE1YXVj0gGGAkFVX3lxTFBObkJOU25VLUVzR1ZTRElqWnRleTllZUZDajZmN2N3SFFUcEwyM2dIRi1CSFZYRDJLQ0VIY002ZFVpNk9ONlNtMTF4NFM1ZmZURUkybVdjY1RDUHIwWmlEQVhrRUxsMzBwYnlCWGVBZ0ZrUlJqWjhzeE5ELVVfMlIyUmZCWXZmbE1RWVlmZ2dPUnA5X09leEJTNXJRanpIbDVqSndIWm0xYnF1RmpzTXpKbDB2VU5sakNrVDl3SDgxYUJDNjZVM1pqOHBWeFFHNmdJbUtvVF9RZERqZUU1TlZmUUEtQ3A0YVFYeTJOMjFuQkZ3ZkdzeW5aTE94R1lWZGtkZzluY1E?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T13:44:02+00:00", "published_display": "07 Jul 2026 13:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals updates investors on rare disease portfolio and Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOWS1KdUtzVGZadVlBa3ZneXhwT0g0d1VQVERWZ2JrWk5qMU1qY0hYNW9FRWlCZl84VTJ1c0RUQjRPaFhqS3VhNjNRNFAzVnFXM0JZeDJyWmxTN0ROX2dVRGtHWDV3RGtSWUpYVDVFaXFrX0ZNeU1nMEszdEROT2x3aElIelZJWnFLVzNhbFEzM3ZnQjNXX29HcjM2ckxtSXRKZWJ2UnJ5V05jM0U2R1lOdlRFREtTc1JyWEJsRHEyUmZjZkFxUXBCR01n?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T13:36:45+00:00", "published_display": "07 Jul 2026 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQcWl6V3FGVGl0b1hmdkxhdVFCNmhlcmNUN2RSamdjMXZXelhRdXRyOUE5RVIxTHZET3J2VnRoYmlTTEhaOW0zMlhYVi1IaXYwSmhOcXpJRzMyZUtsTXlRUHpHanMwNnNMTjJhVGEtNG9XZmYtOVJ4UE56VGJXaGRodmw4WDViZnVLd2pSOXVqN1RQWWU3M2ZYRTJQcHZmRGNTZGZxSUVTaFl4bGFXVXZ4Xw?oc=5", "source_name": "Market source", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) Chief Strategy Officer named as insider in Form 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQZ0FWWU5oUkl4MjBLdWhJQWNLa3JRZ1ZxQlVhOFNobXptSnprdVZLMDJuREdGdlcxR2c2dUpmVVByZ3I5Z0VmMFZwclp3cnJ2SXE4X0ZsanVGa1VaTURsQlYxbTRRMm9SMlRSQ0xyNmFyQkRDQUxkZ0FlcE1ya3RHSnFwRjBwWnA0cElBT2VIYnRCbUtNTzF1UUtGOEtlaXotdWlLcTcwcVN4NkJKQy1DSlpTTG5XLTAtU0dhU3Y4ZFVxYkpjLUFJMEFEcw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals updates investors on business progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNb0VhR0pEbWlTeEp5bVhTWDZJU0k5UXkzbTlNWXFtdm5yamRJZFVCYTRCV25QTkFRLTlZNmUxNjFHUERhWm5zaUE3cW40UmpPVmp4T2pqRTRZdFNTTkRidWlMWDV3bXFSTFFsOUNBV3dYRHIwaVRBV1V1c3dyRVZjdFhUZjhBZk5aeUdnaVkzaHJPLU4zRVpucUxnVmpmV0NZcktib0xuU2EyRkQ0NHlfNXRmaFVfRjdfM1haNmRR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T16:16:43+00:00", "published_display": "03 Jul 2026 16:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOdU5uYXVxQUY5TVdoZExKRFJGd0hpTkVDcnlFQTFlNXcwNEZxTHZQVEptanBoTmNoMjNWaEliem5LYXBQUnRneE5CaWpkUW9TeWQ0NldidV9NckxBR1JMQ1JTTHRNWEhheG9nNDREb3dEeFgwaUN5eW1EV0ZydVh0UGtGV3UzaTFJNDF6ZmRwSmVsX2lydlhVUDlqNXh2Z0d0Y1VySXBGRnNjR09tdFlqbDZ3?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNd0JfRVdaVHRhOTktQk42bW1lUGltMWVzSXo1djNJeDNZay1JaGdtQldFMmw0d255c2hPOEF2MkZjdFl4Y0M2NEplQ0Y5b0JBc1hISlBiam9CUHRyVjZkWm83MTNoeDZzdnVaZHZKTHdlRmlvNW5saUwtME9Tc0pFdDQtRHRGNnA4S3JwWURjQ05sVGtRZ3FwZEh2RnBTVWY1UVZ3OWYwVWJhZUowM2toWg?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 5.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQa0RZV1FERVJRaHg5OWw4SUxCYTl1VjlwTXZrRXNKeDBzejhacEE3RkFKY0oyd0UwcHllcFNWMHk1N0RRYjZfcHMzWFdnQUNYNVh1b3JHWGJvWlVhNEpTXzFlV3ROXzlpNTNfMnN6Nm1WcTM2NmVTYS1YUHRKbXVBaUhZR0xIaEVPYWZLNkRJNlo0RzBvVDlTMDNfeWFYaVR2S3hhU2FHQW5pZUxkRHhDQkdhalhIYzRYb2VlaHZZMVBGUWJoNUtWbTU5VXJLQ3VpZzE0?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-30T00:01:06+00:00", "published_display": "30 Jun 2026 00:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Kiniksa Pharmaceuticals International to $72 From $59, Keeps Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-kiniksa-110951947.html", "source_name": "MT Newswires", "published_at": "2026-06-29T11:09:51+00:00", "published_display": "29 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (BOATS:KNSA)", "summary": "This article provides an overview of Kiniksa Pharmaceuticals International, plc (KNSA) stock, including its financial actuals and estimates. It details analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net income, and EBI", "url": "https://www.tradingview.com/symbols/BOATS-KNSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:07", "published_display": "26 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International PLC (KNSA) Stock Down 3.8% but Still Overvalued -- GF Score: 56/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxON1ZzdVVnSHBtdkhzNlByUmU1ajZwLWlpbnlEVkpXa3B3aVYtOFNSbjdLZ2Zya0hRTXAxRXc4RDJXWGszZnU4ZmJxZFhTRmN0V1hURkhQMEJSQXZMWW9MN2lkZXRoMDBRSF80TDlNdjREdWRiVWVJREU3R0doUTJHd0djc1pJbkxrdkgtMlJaaFZMQy1HQWNHM2lWWm5qYjVLRVNkZTdWN2h5cm1oMmxzTmM3bjhmVzE4NlpYMEZUWW9mbGV6NTNucEpGMUNaSFpj?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-26T00:21:25+00:00", "published_display": "26 Jun 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KNSA/N Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Kiniksa Pharmaceuticals International, plc Class A (KNSA/N) stock, including analyst price targets and future predictions. It details financial metrics such as EPS, revenue, market capitalization, and upcoming earnings dates, along with histor", "url": "https://www.tradingview.com/symbols/BMV-KNSA/N/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:07", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQci1mNXA5eDAwUG9ic1NOMmxzbWlKVUg3bTYtWDB6U2p5SGVkYTlLMEJUWW5BalV4OXRSd1JlWVgyNS12Q19sdUYybjEwRnFfTXJQLXR3Tl91aTZiMnJkbW82eTE2VnJzZmd0UTBvaHYzNl8tQkpBR0lyVlg2cnVwLU5sRk1EOXoyWHFfZXAyZDEyQUtJSTlwcmlZaW9OV0g2WjgxS0ZzaENyQzY1aUNkNWN3?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals stock hits all-time high of 59.89 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNa0lfSm9kRm84ZW9sQ3hSaDVaajBicXVPVkxMd29saVFIck1uUFNPMkowR2pFUnlJTlFtLXNqNzJaZFJMc0NyNzFVNkZWTzE4Ny16M0IzU2gxY1k5dlpsQkluZFBmY1JNQk1WdnpCR1VSVVg3NHdyUS15UGQ0T3dUaF9tODFKdFUza1pueEhtMnp6ZjU1WGI5T2ZwbDNOYi14UG5zT2o1STRZUDFEUFVnQ29KdzYtVUk?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNbnY1ZmFRUm11TVFqNWZIUUlrRkZUUGRuR1VmM1RXZ0F0MklRdjBqZHZfSEJWRDREMkN6R3dDaFIyalpGRkJZSXJQbDgyY0drTE5SenV1SWpBOWJORGFFN2xwbkpoQ0hRREZHQzFacDR3dHlVSzVFZk8ySE4zRjJMRWRRb1FRMHViUzZHdEdPOHJpUHU5dFRHWjBSWWJkMTZJalFlcmZQQ1BwWU0?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPa0NEazl3TldfSVNlUFRZZGlsemRqWDhtdGlBdTZITUZnRWRhVDhsVThmWUN0TkFjVjhEZXBOS3djVUxucEJMQjJYSS04ZUJkMGJfZU9pRW1QbGFQU0RndEdHa2E2RmJRR19McVQzSk5USmhMYkpFaHFCOXRZT245MlhyREE4SGdPTmppdWpKbEVMTVlfbmY0eGhCaTVUd0xRQlB6S1FwcEhvOUhvbzJuTA?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director receives RSUs and options in equity grants", "summary": "Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported exercising 2,799 vested Restricted Share Units (RSUs) and receiving new equity grants on May 29, 2026. These new grants include 2,026 RSUs and options for 12,158 Class A Ordinary Shares with an exercise p", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-6525fa05d906.html", "source_name": "Stock Titan", "published_at": "2026-06-03T14:39:39", "published_display": "03 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) awards RSUs and options to Baker-affiliated board representatives", "summary": "Kiniksa Pharmaceuticals International, plc (KNSA) granted restricted share units (RSUs) and non-qualified share options to three Baker-affiliated directors, including Felix J. Baker. Each director received 2,026 RSUs and 12,158 share options with a strike price of $48.38, as comp", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-29aaf6ed096a.html", "source_name": "Stock Titan", "published_at": "2026-06-03T07:39:39", "published_display": "03 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director Malley exercises RSUs and receives new option grant", "summary": "Kiniksa Pharmaceuticals director Thomas Malley recently exercised 2,799 Restricted Share Units and received new grants, including 2,026 RSUs and a share option for 12,158 Class A Ordinary Shares, with an exercise price of $48.38 per share. These transactions, which occurred on Ma", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-35d47ea1fd3a.html", "source_name": "Stock Titan", "published_at": "2026-06-03T02:40:25", "published_display": "03 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) director exercises 2,799 RSUs and gets options on 12,158 shares", "summary": "Kiniksa Pharmaceuticals director Tracey L. McCain exercised 2,799 Restricted Share Units (RSUs) converting them into Class A Ordinary Shares, increasing her direct holdings to 15,345 shares. She also received new grants of 2,026 RSUs and share options for 12,158 Class A Ordinary ", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-25529e22b160.html", "source_name": "Stock Titan", "published_at": "2026-06-03T00:39:39", "published_display": "03 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals (KNSA) director gains shares and new equity awards", "summary": "Kiniksa Pharmaceuticals director Cole G. Bradley reported exercising 2,799 Restricted Share Units (RSUs) into Class A Ordinary Shares, increasing his direct holdings to 15,345 shares. He also received new equity awards, including 2,026 RSUs and options on 12,158 Class A Ordinary ", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-315cd0af69a8.html", "source_name": "Stock Titan", "published_at": "2026-06-03T00:39:39", "published_display": "03 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director exercises RSUs and receives new option grant", "summary": "Kiniksa Pharmaceuticals International, plc director Richard S. Levy recently exercised 2,799 Restricted Share Units (RSUs), converting them into Class A Ordinary Shares, bringing his direct holdings to 21,956 shares. Concurrently, he received new grants including 2,026 RSUs and a", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-4799ca5b4afc.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:39:39", "published_display": "02 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director Popovits exercises 2,799 RSUs and receives 12,158-share option grant", "summary": "Kiniksa Pharmaceuticals International, plc director Kimberly J. Popovits reported routine equity compensation transactions. On May 29, 2026, she exercised 2,799 Restricted Share Units (RSUs) and received new grants of 2,026 RSUs and a share option for 12,158 Class A Ordinary Shar", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-0e7bd5ac068b.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:39:39", "published_display": "02 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO-linked trust converts 900,000 Kiniksa (NASDAQ: KNSA) Class B shares", "summary": "A trust associated with Kiniksa Pharmaceuticals' CEO, Sanj K. Patel, converted 900,000 Class B Ordinary Shares into Class A Ordinary Shares. This transaction, a non-cash derivative conversion at $0.00 per share, resulted in the trust holding 951,794 Class A and 626,160 Class B sh", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-a309cc6b8b2f.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:39:39", "published_display": "02 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International, plc Files Form 8-K Detailing Annual Meeting Results and Company Information", "summary": "Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) announced the results of its 2026 Annual Shareholder Meeting held on May 29, 2026. All proposals, including the re-election of directors, appointment of auditors, and approval of executive compensation, were passed by shar", "url": "https://www.minichart.com.sg/2026/05/31/kiniksa-pharmaceuticals-international-plc-files-form-8-k-detailing-annual-meeting-results-and-company-information/", "source_name": "Minichart", "published_at": "2026-05-31T10:39:58", "published_display": "31 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals Files 8-K Disclosing Waiver of Share Conversion Rights with Baker Brothers Life Sciences 9", "summary": "Kiniksa Pharmaceuticals International, plc has entered into a Deed of Waiver with its major shareholder, Baker Bros. Advisors LP, restricting Baker Bros.'s ability to convert shares if it would result in beneficial ownership of more than 49.9% of Kiniksa's voting rights. This agr", "url": "https://www.minichart.com.sg/2026/05/27/kiniksa-pharmaceuticals-files-8-k-disclosing-waiver-of-share-conversion-rights-with-baker-brothers-life-sciences-9/", "source_name": "Minichart", "published_at": "2026-05-31T10:09:21", "published_display": "31 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Shareholders Reelect Directors and Approve Auditor Mandates", "summary": "Kiniksa Pharmaceuticals shareholders reelected Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart as Class II directors to serve until the 2029 Annual Meeting. They also approved PricewaterhouseCoopers LLP as the U.K. statutory auditor and U.S. independent registered public a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/KNSA/pressreleases/2219537/kiniksa-shareholders-reelect-directors-and-approve-auditor-mandates/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T02:40:25", "published_display": "31 May 2026 02:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) investors approve board, PwC auditor roles and pay", "summary": "Kiniksa Pharmaceuticals International, plc shareholders approved all proposals at their Annual Meeting on May 29, 2026. This included the re-election of three Class II directors (Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart), and the appointment and remuneration of Pric", "url": "https://www.stocktitan.net/sec-filings/KNSA/8-k-kiniksa-pharmaceuticals-international-plc-reports-material-event-3e96291ecc7c.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:10:06", "published_display": "29 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) sets 49.9% voting cap for Baker Bros. conversions", "summary": "Kiniksa Pharmaceuticals International, plc has entered into a deed of waiver with Baker Bros. Advisors LP and affiliated funds, capping their ability to convert shares if it results in them beneficially owning more than 49.9% of Kiniksa's outstanding voting rights. This agreement", "url": "https://www.stocktitan.net/sec-filings/KNSA/8-k-kiniksa-pharmaceuticals-international-plc-reports-material-event-8c00e74a18e5.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:40:38", "published_display": "26 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baker Bros sets 49.9% voting cap in Kiniksa (NASDAQ: KNSA)", "summary": "Baker Bros. Advisors has filed an amendment to its Schedule 13D for Kiniksa Pharmaceuticals International, plc, disclosing a Deed of Waiver that limits their voting rights in Kiniksa to 49.9%. This agreement prevents the conversion of certain share classes if it would cause their", "url": "https://www.stocktitan.net/sec-filings/KNSA/schedule-13d-a-kiniksa-pharmaceuticals-international-plc-amended-majo-a221559176c3.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:40:38", "published_display": "26 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdlNHN3N2dG5VeTM4b0RYdWN2c1lRdkhHQWFvT3hKeHV3RjJibkJKdHF1UG9kVVdEbkswYnU0dUE2OE1DQXpUZTlLN0wxX25VUmNJMnY0QTJ5V05iLXIxT0hLNHp2OWF2MGJmMERXVDI1aW9SNnpMMmhncnV1OW1zbXVleWozLVdwLTNOb1FzXzlUVU5UNk03OGptd05lVVpsSXE5LW83dDhlSlk?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZExEV0FialpsWWQ4aVpJY1J5OEZaeEhvYnJ5c0NDdEMwMVVGMkVGQkpQRWppNlBqN1hiYk54dTJXWTJUNmR3Yno2V0JZTUQ3YTlkLXlrUGpiNXBTTU1hQXlhRHBlRURobjE1aTBHOW04OGE0V216UUl2RUdLRWhMV2tXdkp6S29ua2o5YUxRVjFNOThjdURWZEZ4dXlWSGZhRlIwWDlmTVB3am5Ra2lEc2pLbmx4UUk?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC amends filing showing 6,787,700.23 Kiniksa holdings (KNSA)", "summary": "FMR LLC has filed an amendment to its Schedule 13G, reporting beneficial ownership of 6,787,700.23 shares of Kiniksa Pharmaceuticals International (KNSA) Class A common stock. This updated filing indicates that FMR LLC holds 14.8% of the class. The disclosure specifies that FMR L", "url": "https://www.stocktitan.net/sec-filings/KNSA/schedule-13g-a-kiniksa-pharmaceuticals-international-plc-amended-pass-bdd4f0e1c3f4.html", "source_name": "Stock Titan", "published_at": "2026-05-06T15:39:57", "published_display": "06 May 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options", "summary": "Kiniksa Pharmaceuticals International, plc's Chief Medical Officer, John F. Paolini, executed an exercise-and-sell transaction on May 1, 2026. He exercised options to acquire 58,424 Class A Ordinary Shares at $10.36 per share and simultaneously sold the same number of shares in t", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-704661f9631f.html", "source_name": "Stock Titan", "published_at": "2026-05-05T20:38:43", "published_display": "05 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026)", "summary": "Kiniksa Pharmaceuticals International plc announced the resignation of its Chief Strategy Officer, Eben Tessari, effective May 15, 2026. Mr. Tessari will transition to a consulting and advisory role for the company's Science and Research Committee, assuaging concerns about abrupt", "url": "https://www.minichart.com.sg/2026/05/02/kiniksa-pharmaceuticals-international-plc-files-8-k-announces-consulting-agreement-details-and-company-information-april-30-2026/", "source_name": "Minichart", "published_at": "2026-05-03T01:09:33", "published_display": "03 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan", "summary": "Kiniksa Pharmaceuticals International, plc CEO Sanj K. Patel exercised options to acquire 48,565 Class A Ordinary Shares at $30.93 per share and subsequently sold all of them in an open-market transaction at a weighted-average price of $54.02 per share. This transaction was execu", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-40bdb8feb6ff.html", "source_name": "Stock Titan", "published_at": "2026-05-01T20:39:39", "published_display": "01 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNcHU0VGt5U1duaFU5WlZNekdKbllleVJvWFBpWDYySU8zSDI5RGg4cHljQlE2SFhTNjM1MVpEaWlpYmliRFFrRDNVQ2RKeGhyRDdtT0M2TjFzaFZRTXZrRGh6bGlnN2wtOE9wZ3lGcXF2V0M5Z3hGcGtRbGlBMXFVaE5TOE95cndCR19xaFA3clJyenQ4Vmh4TmNlU2hybDB1VmFEd0RfbzhOa3JrYm45XzVGY1A?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) CEO\u2019s plan-based option exercises and 508K share sales detailed", "summary": "Kiniksa Pharmaceuticals International, plc CEO Sanj K. Patel exercised options for 508,339 Class A Ordinary Shares and subsequently sold an equal number of shares between April 28-30, 2026, at prices ranging from approximately $50.00 to $54.23 per share. These transactions were e", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-a8fe8e7a9761.html", "source_name": "Stock Titan", "published_at": "2026-04-30T22:10:13", "published_display": "30 Apr 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KNSA SEC Filings - Kiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms", "summary": "This article provides a comprehensive overview of Kiniksa Pharmaceuticals International, plc's (KNSA) SEC filings available on Stock Titan. It details the types of filings, such as 10-K, 10-Q, and 8-K, and explains their importance for investors tracking financial results, clinic", "url": "https://www.stocktitan.net/sec-filings/KNSA/page-10.html", "source_name": "Stock Titan", "published_at": "2026-04-29T23:09:14", "published_display": "29 Apr 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan", "summary": "Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised options to acquire 13,099 Class A Ordinary Shares at $14.33 per share and subsequently sold them at a weighted average price of $50.10. This transaction was conducted under a pre-arranged Rule 10b5-1 pla", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-fa45bcf31958.html", "source_name": "Stock Titan", "published_at": "2026-04-29T21:08:39", "published_display": "29 Apr 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (NASDAQ: KNSA) insider sale and cashless exercise flagged in Form 144", "summary": "Kiniksa Pharmaceuticals International, plc filed a Form 144 detailing proposed and recent insider sales of Class A Ordinary Shares. The filing indicates a cashless exercise broker payment scheduled for April 28, 2026, and a prior sale on April 6, 2026, of 7,278 shares by Sanj K P", "url": "https://www.stocktitan.net/sec-filings/KNSA/144-kiniksa-pharmaceuticals-international-plc-sec-filing-5d9f9ad7448c.html", "source_name": "Stock Titan", "published_at": "2026-04-28T20:38:51", "published_display": "28 Apr 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) CAO sells 6,625 shares in Rule 10b5-1 trade", "summary": "Kiniksa Pharmaceuticals International, plc's Chief Accounting Officer, Michael R. Megna, reported the sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and after the sale, Megna", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-2779e2d1f8d2.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:38:47", "published_display": "13 Apr 2026 20:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan", "summary": "Kiniksa Pharmaceuticals International, plc's Chief Operating Officer, Moat Ross, sold 1,703 Class A Ordinary Shares at $46.69 per share on April 9, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on November 13, 2024. Following the s", "url": "https://www.stocktitan.net/sec-filings/KNSA/form-4-kiniksa-pharmaceuticals-international-plc-insider-trading-acti-f0b1688f50bc.html", "source_name": "Stock Titan", "published_at": "2026-04-13T20:38:47", "published_display": "13 Apr 2026 20:38", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa (KNSA) Form 144: 6,625 Class A shares tied to restricted stock lapses", "summary": "Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 indicating proposed dispositions of 6,625 Class A ordinary shares. These shares are linked to restricted stock lapses that occurred on April 1, 2026 (4,359 shares) and April 7, 2026 (2,266 shares). This admini", "url": "https://www.stocktitan.net/sec-filings/KNSA/144-kiniksa-pharmaceuticals-international-plc-sec-filing-67ea559f7c7a.html", "source_name": "Stock Titan", "published_at": "2026-04-09T19:39:41", "published_display": "09 Apr 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa\u2019s Heart\u2019s Home Campaign Targets ARCALYST Growth In Pericarditis Market", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kiniksa Pharmaceuticals International (KNSA) Profitability Shift Tests Bullish High Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 55, "sentiment_summary": {"positive": 20, "negative": 2, "neutral": 33, "score": 56, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 23.1, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 3.1, "count": 5}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 63.44, "latest_week": "2026-07-10", "one_week_move": -1.7, "four_week_move": 22.3, "twelve_week_move": 41.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.080281, "market_dynamics_buy_signal": false, "relative_strength": 26.351963, "fair_value_gap": 123.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.4771, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.7% over one week, +22.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 23}, {"label": "Market source", "count": 8}, {"label": "simplywall.st", "count": 4}, {"label": "MarketBeat", "count": 3}, {"label": "GuruFocus", "count": 3}, {"label": "Ad Hoc News", "count": 3}, {"label": "Minichart", "count": 3}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 7}, {"label": "Analyst action", "count": 5}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.7% over one week, +22.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Kiniksa Pharmaceuticals: Leader In Pericarditis Merits Hold Rating After Recent Gains"}], "updated_at": "2026-07-16T14:30:27.913124+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}